Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole

Itraconazole increases the risk of skeletal muscle toxicity of some 3‐hydroxy‐3‐methylglutaryl coenzyme A (HMG‐CoA) reductase inhibitors by increasing their serum concentrations. We studied possible interactions of itraconazole with simvastatin and pravastatin.

[1]  S. Singhvi,et al.  Disposition of pravastatin sodium, a tissue-selective HMG-CoA reductase inhibitor, in healthy subjects. , 1990, British journal of clinical pharmacology.

[2]  P. Neuvonen,et al.  Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid , 1996, Clinical pharmacology and therapeutics.

[3]  T. Leemann,et al.  In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors , 1996, European Journal of Clinical Pharmacology.

[4]  Scandinavian Simvastatin Survival Study Group.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) , 1994, The Lancet.

[5]  B. Arison,et al.  In vitro and in vivo biotransformation of simvastatin, an inhibitor of HMG CoA reductase. , 1990, Drug metabolism and disposition: the biological fate of chemicals.

[6]  M. Horn.  Coadministration of itraconazole with hypolipidemic agents may induce rhabdomyolysis in healthy individuals. , 1996, Archives of dermatology.

[7]  D. McTavish,et al.  Pravastatin , 2012, Drugs.

[8]  J. Kolars,et al.  CYP3A gene expression in human gut epithelium. , 1994, Pharmacogenetics.

[9]  U. Christians,et al.  Comparison of pravastatin and lovastatin in renal transplant patients receiving cyclosporine. , 1996, Transplantation proceedings.

[10]  H. Iwabuchi,et al.  Biotransformation of pravastatin sodium (I). Mechanisms of enzymic transformation and epimerization of an allylic hydroxy group of pravastatin sodium. , 1993, Biochemical and biophysical research communications.

[11]  R. Lees,et al.  Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent itraconazole. , 1995, The New England journal of medicine.

[12]  D. Illingworth,et al.  Myolysis and acute renal failure in a heart-transplant recipient receiving lovastatin. , 1988, The New England journal of medicine.

[13]  B. Davis,et al.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. , 1996, The New England journal of medicine.

[14]  F. Brunner‐Ferber,et al.  Comparative Pharmacokinetics of Lovastatin, Simvastatin and Pravastatin in Humans , 1992, Journal of clinical pharmacology.

[15]  R. Stubbs,et al.  Determination of mevinolin and mevinolinic acid in plasma and bile by reversed-phase high-performance liquid chromatography. , 1986, Journal of chromatography.

[16]  A. Y. Lu,et al.  Biotransformation of lovastatin. IV. Identification of cytochrome P450 3A proteins as the major enzymes responsible for the oxidative metabolism of lovastatin in rat and human liver microsomes. , 1991, Archives of biochemistry and biophysics.

[17]  G. Granneman,et al.  Use of In Vitro and In Vivo Data to Estimate the Likelihood of Metabolic Pharmacokinetic Interactions , 1997, Clinical pharmacokinetics.

[18]  A. Edebo,et al.  Determination of itraconazole in serum with high-performance liquid chromatography and fluorescence detection. , 1990, Journal of chromatography.

[19]  T. Kinoshita,et al.  Metabolism of pravastatin sodium in isolated rat hepatocytes. II. Structure elucidation of the metabolites by n.m.r. spectroscopy. , 1991, Xenobiotica; the fate of foreign compounds in biological systems.

[20]  S. Hall,et al.  The interaction of diltiazem with lovastatin and pravastatin , 1998, Clinical pharmacology and therapeutics.

[21]  HOMAS,et al.  The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels , 2000 .

[22]  J. D. Karkas,et al.  Plasma concentration profiles of simvastatin 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitory activity in kidney transplant recipients with and without ciclosporin. , 1993, Nephron.

[23]  M. Arnold,et al.  Determination of pravastatin sodium and its major metabolites in human serum/plasma by capillary gas chromatography/negative ion chemical ionization mass spectrometry. , 1989, Biomedical & environmental mass spectrometry.

[24]  T. Kinoshita,et al.  Metabolism of pravastatin sodium in isolated rat hepatocytes. I. Glutathione conjugate formation reaction. , 1992, Xenobiotica; the fate of foreign compounds in biological systems.

[25]  I. Chen,et al.  Metabolic disposition studies on simvastatin, a cholesterol-lowering prodrug. , 1990, Drug metabolism and disposition: the biological fate of chemicals.

[26]  B. Matuszewski,et al.  Determination of the HMG-CoA reductase inhibitors simvastatin, lovastatin, and pravastatin in plasma by gas chromatography/chemical ionization mass spectrometry. , 1993, Biological mass spectrometry.

[27]  M. Fromm,et al.  Expression of CYP3A4, CYP3A5 and CYP3A7 in human duodenal tissue. , 2003, British journal of clinical pharmacology.